Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as... see more

Recent & Breaking News (NDAQ:EQ)

Equillium Announces Poster Presentations at IMMUNOLOGY2026(TM), the Annual Meeting of the American Association of Immunologists

GlobeNewswire 8 days ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 2, 2026

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

GlobeNewswire March 25, 2026

Equillium to Participate in the 38th Annual Roth Conference

GlobeNewswire March 18, 2026

Equillium Announces $35 Million Financing with RA Capital Management

GlobeNewswire March 13, 2026

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

GlobeNewswire February 25, 2026

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2026

Equillium to Participate in Upcoming Investor Conferences

GlobeNewswire November 20, 2025

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

GlobeNewswire November 13, 2025

Equillium to Participate in Upcoming Investor Conferences

GlobeNewswire November 4, 2025

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 3, 2025

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

GlobeNewswire October 22, 2025

Equillium Announces Leadership and Corporate Updates

GlobeNewswire October 6, 2025

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 3, 2025

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Business Wire August 29, 2025

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Business Wire August 11, 2025

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Business Wire August 4, 2025

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Business Wire May 6, 2025

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Business Wire May 1, 2025

Equillium Announces Feedback from the U.S. Food and Drug Administration

Business Wire April 24, 2025

Podcasts